6/28/23, 12:51 AM AXIOMATIC-TKR (high-dose) Pathway Feedback Search Clinical Topics Home Studies AXIOMATIC TKR (high-dose) AXIOMATIC TKR (high-dose) Disease Knee osteoarthritis Trial question What is the role of high-dose milvexian in the prevention of VTE in patients undergoing knee arthroplasty? Study design Multi-center Open label RCT Population Characteristics of study participants 68.0% female N = 383 32.0% male 383 patients (260 female, 123 male) Inclusion criteria: patients, aged 50 years, undergoing elective unilateral total knee arthroplasty Key exclusion criteria: contraindications to enoxaparin; history of severe hepatic impairment or previous VTE; long-term use of antithrombotic therapy other than aspirin; inability to undergo venography Interventions N=131 milvexian (at a dose of 200 mg BID) N=252 enoxaparin (at a dose of 40 mg once daily) Primary outcome https://web.pathway.md/studies/recUBhUYIFebmjQnN 1/2 6/28/23, 12:51 AM AXIOMATIC-TKR (high-dose) Pathway Venous thromboembolism 21.0 % 21 15.8 % 10.5 % 8 Significant decrease 5.3 % NNT = 8 0.0 % Milvexian Enoxaparin Significant decrease in VTE (8% vs. 21%; RR 0.37, 95% CI 0.19 to 0.69) Safety outcomes No significant differences in any bleeding, major bleeding or clinically relevant nonmajor bleeding. Conclusion In patients, aged 50 years, undergoing elective unilateral total knee arthroplasty, milvexian was superior to enoxaparin with respect to VTE. Reference Jeffrey I Weitz, John Strony, Walter Ageno et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 Dec 2;385(23):2161-2172. Open reference URL https://web.pathway.md/studies/recUBhUYIFebmjQnN 2/2